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OBJECTIVE— In participants of the Diabetes Prevention Program (DPP) randomized to
intensive lifestyle modification (ILS), meeting ILS goals strongly correlated with prevention of
diabetes in the group as a whole. Men met significantly more ILS goals than women but had a
similar incidence of diabetes. Therefore, we explored sex differences in risk factors for diabetes
and the effect of ILS on risk factors.
RESEARCHDESIGNANDMETHODS— Baseline risk factors for diabetes and percent
change in risk factors over the first year in men versus women were compared using Wilcoxon’s
rank-sum tests.
RESULTS— At baseline, men were older and had a larger waist circumference; higher fasting
plasma glucose concentration, caloric intake, and blood pressure; and lower HDL cholesterol
and corrected insulin response than women, who were less physically active and had a higher
BMI (P 0.01 for all comparisons). Over the first year of the DPP, no sex difference in risk factors
for diabetes was observed for those who lost 3% body weight. Weight loss of 3–7% body
weight yielded greater decreases in 2-h glucose (P 0.01), insulin concentration (P 0.04), and
insulin resistance (P 0.03) in men than in women. Weight loss of7% body weight resulted
in greater decreases in 2-h glucose (P 0.01), triglyceride level (P 0.01), and A1C (P 0.03)
in men than in women.
CONCLUSIONS— Weight loss 3% body weight yielded greater reduction in risk factors
for diabetes in men than in women. Despite the more favorable effects of ILS in men, baseline risk
factors were more numerous in men and likely obscured any sex difference in incident diabetes.
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The global epidemic of type 2 diabe-tes has led to a number of large clin-ical trials examining the feasibility
and efficacy of prevention strategies, in-
cluding both lifestyle modification and
drug therapy (1–4). Despite their large
number of participants, none of these tri-
als were specifically designed to compare
sex differences in adherence to or benefit
from the interventions. The Malmo Study
(1) included only men. The Da Xing
Study included equal numbers of men
and women with impaired glucose toler-
ance, but no sex-specific comparisons
were reported (3). The Finnish Diabetes
Prevention Study reported a 63% reduc-
tion in the incidence of diabetes among
men versus a 54% reduction among
women with impaired glucose tolerance
in a comparison of intensive lifestyle
modification (ILS) to no lifestyle interven-
tion (4). However, the authors do not re-
port whether this sex difference was
statistically different or whether men met
more lifestyle goals than women. The U.S.
Diabetes Prevention Program (DPP) also
studied adults with impaired glucose tol-
erance and found that men were signifi-
cantly more physically active, lost more
weight, and met more of the goals of ILS
than women; nevertheless, reduction in
incidence of diabetes in the lifestyle group
did not differ significantly by sex (2). Re-
sults from the DPP suggest that sexual di-
morphism may exist with regard to
adherence to or benefit from ILS, but its
magnitude or mechanism has not been
explored. The aim of this paper was to
examine sex differences in risk factors for
diabetes and compare the effect of lifestyle
changes on cardiometabolic and diabetes
risk in men versus women.
RESEARCH DESIGN AND
METHODS— The DPP was a ran-
domized clinical trial conducted at 27
sites enrolling individuals who were at
high risk for diabetes. Detailed methodol-
ogy has been reported (5), and the proto-
col is available at http://www.bsc.gwu.
edu/dpp. The institutional review board
at each center approved the protocol, and
all participants gave written informed
consent before participation.
Eligibility criteria included age 25
years, BMI 24 kg/m2 (22 kg/m2 in
Asians), and plasma glucose concentra-
tion 5.3–6.9 mmol/l (6.9 mmol/l in the
American Indian clinics) in the fasting
state and 7.8–11.0 mmol/l 2 h after a 75-g
oral glucose tolerance test (OGTT). Indi-
viduals were excluded if they were taking
medicines known to alter glucose toler-
ance or had significant illness.
Interventions
Eligible participants were randomly as-
signed to one of three interventions: 1)
placebo twice daily and standard lifestyle
recommendations; 2) metformin, at a
dose of 850 mg twice daily, and standard
lifestyle recommendations; or 3) ILS. This
paper considers sex differences only in
the lifestyle and placebo groups.
The goals for the participants as-
signed to ILS were to achieve and main-
● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
From the 1University of Colorado Health Sciences Center, Aurora, Colorado; the 2Coordinating Center,
George Washington University, Rockville, Maryland; the 3University of Tennessee, Memphis, Tennessee;
the 4Joslin Diabetes Center, Boston, Massachusetts; 5Indiana University, Indianapolis, Indiana; the 6Albert
Einstein College of Medicine, Bronx, New York; and the 7University of California, San Diego, La Jolla,
California.
Corresponding author: The Diabetes Prevention Program Coordinating Center, dppmail@biostat.
bsc.gwu.edu.
Received 4 January 2007 and accepted 18 March 2008.
Published ahead of print at http://care.diabetesjournals.org on 20 March 2008. DOI: 10.2337/dc07-2390.
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
C a r d i o v a s c u l a r a n d M e t a b o l i c R i s k
O R I G I N A L A R T I C L E
1416 DIABETES CARE, VOLUME 31, NUMBER 7, JULY 2008
tain a weight reduction of at least 7% in
initial body weight through a healthy low-
calorie, low-fat diet and to engage in
physical activity of moderate intensity,
such as brisk walking, for at least 150 min
per week.
Outcome measures
The primary outcome was diabetes, diag-
nosed on the basis of a confirmed value
for plasma glucose of7.0 mmol/l in the
fasting state or 11.1 mmol/l 2 h after a
75-g OGTT. Self-reported levels of leisure
physical activity were assessed semi-
annually with the Modifiable Activity
Questionnaire (5). The physical activity
level was calculated as the product of the
duration and frequency of each activity
(in hours per week) weighted by an esti-
mate of the metabolic equivalent of that
activity (MET) and summed for all activ-
ities performed, with the result expressed
as the average MET-hours per week for
the previous year. Usual daily caloric in-
take during the previous year, including
calories from fat, carbohydrate, protein,
and other nutrients, was assessed at base-
line and at 1 year with the use of a modi-
fied version of the Block food frequency
questionnaire (5). Weight was measured
semi-annually and compared with previ-
ous measures to calculate weight change.
Venous blood was obtained and pro-
cessed at each DPP clinical site following
DPP protocol (available at https://www.
bsc.gwu.edu/dpp/protocol.htmlvdoc).
Serum and plasma samples were stored at
20°C for several days and then shipped
in batches on dry ice to the same central
laboratory. Measurement methods for
glucose, insulin, triglyceride, HDL cho-
lesterol, and A1C have been published
(5).
Measures of insulin secretion (cor-
rected insulin response [CIR]) and insulin
action (homeostasis model assessment of
insulin resistance [HOMA-IR]) were cal-
culated and compared between men and
women using validated indexes (6,7).
These indexes were calculated as follows:
CIR  [100  30 min insulin]/[30
min glucose  (30 min glucose  70)]
and
HOMA-IR  1/{22.5/[fasting insu-
lin  (fasting glucose/18.01)]}.
Statistical analysis
Wilcoxon’s rank-sum tests were used to
compare continuous baseline characteris-
tics between the sexes, and data were re-
ported as median  interquartile ranges
because of their nonnormal distribution.
Pearson’s 2 tests were used to compare
categorical baseline characteristics be-
tween the sexes. The effect of sex on the
development of diabetes was modeled us-
ing Cox proportional hazards models.
Wilcoxon’s rank-sum tests were also used
to compare changes in continuous vari-
ables from baseline to the end of year 1.
Pearson’s 2 test was used to compare
manners of progression to diabetes (fast-
ing vs. 2-h glucose concentration vs.
both) at time of diagnosis. All analyses
were conducted using SAS software (ver-
sion 9.1; SAS Institute, Cary, NC).
RESULTS
Demographics
There were twice as many women as men
in both the ILS (734 women and 345
men) and placebo (747 women and 335
men) groups, reflecting the demographic
of the overall cohort. Ethnic distribution
was generally similar in men and women.
At baseline, men were older, had a larger
waist circumference, and had higher ca-
loric intake and blood pressure than
women, who were less physically active
and had a higher BMI (P  0.01 for all
comparisons) (Table 1). Obesity (BMI
30 kg/m2) was present in 56.5% of men
and 73% of women (P  0.0001). Men
and women were comparable in terms of
socioeconomic status (estimated from
employment status, education, annual
family income, marital status, and num-
ber of individuals in household). The
dropout rate during the trial was less than
10% in both men and women.
Meeting goals
In the ILS group, men lost more absolute
weight (6.0 vs. 4.6 kg, P 0.01), a greater
percentage of body weight (8 vs. 7%, P
0.02), and more absolute and percentage
of waist circumference (5.6 cm [5.2%] vs.
4.6 cm [4.4%], P 0.05 for all compari-
sons) than women. Overall, more men
than women achieved the 7% weight loss
goal (46.8 vs. 37.4%, P  0.0004). Men
also reported higher levels of leisure (11.5
vs. 3.2 MET h/week, P 0.001) and rec-
reational (10.6 vs. 6.8 MET h/week, P 
0.05) activity than women. Neither the
absolute daily reduction in calories (P 
0.11) nor the percentage of change in re-
ported caloric intake (P  0.07) differed
by sex. In the placebo group, no sex dif-
ferences were observed with respect to
change in weight, BMI, waist circumfer-
ence, or caloric intake (Table 2).
Sex and ILS effect on
cardiometabolic and diabetes risk
As previously reported, the DPP showed a
58% reduction in conversion to diabetes
among participants randomized to ILS
compared with those randomized to pla-
cebo (2), and the overall treatment effect
did not differ by sex (P 0.71). However,
despite the fact that men in the ILS group
met more of the lifestyle goals than
women, the percentage of diabetes risk
reduction (61.6 vs. 51.8% higher than
placebo, men versus women; P  0.25)
and of participants achieving normal glu-
cose tolerance (37.7 vs. 36.5%, men ver-
sus women; P  0.72) did not differ by
sex.
Baseline measures
We considered whether the lack of greater
benefit in the men in the ILS group could
be related to sex differences at baseline.
Baseline fasting plasma glucose concen-
tration was higher in men than in women
(5.9  0.7 vs. 5.8  0.6 mmol/l, respec-
tively; P 0.01) with no sex difference in
postchallenge glucose concentration (2-h
post-OGTT glucose 9.0  1.6 vs. 8.9 
1.5 mmol/l, P  0.60) or A1C (5.9 
0.5% for both, P  0.94). Despite their
higher fasting glucose levels, men did not
have higher fasting insulin levels at base-
line (138  102 vs. 144  105 pmol/l,
P 0.23). This apparent sex difference in
the insulinotropic response to ambient
glycemia was corroborated by calculation
of the CIR (0.49  0.4 vs. 0.56  0.41,
P  0.01). In contrast, men had similar
whole-body insulin action as assessed by
HOMA-IR (6.0  4.6 vs. 6.0  4.9, P 
0.73). Men also had higher blood pres-
sure (124/80 18/13 vs. 121/78 21/13
mmHG, P  0.01) and lower HDL cho-
lesterol than women at baseline (39 13
vs. 47  16 mg/dl, P  0.01). Compara-
ble sex differences were observed in the
placebo group at baseline (Table 1).
Measures at the end of year 1
It was further considered whether lack of
greater benefit from ILS in men may have
been due to a weaker effect of ILS on risk
factors for cardiovascular disease and di-
abetes in men. To examine the effect of
ILS on risk factors for cardiovascular dis-
ease and diabetes, groups were stratified
by weight loss (3%, 3–7%, and 7%),
as weight loss is more closely related to
diabetes prevention than the manner in
which it occurs (8). Within each weight
loss stratum, changes in activity, calorie
intake, BMI, and percentage of weight loss
Perreault and Associates
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were not different between men and
women. Over year 1 of DPP, as weight
loss increased, fasting and 2-h glucose,
triglycerides, blood pressure, waist cir-
cumference, BMI, A1C, insulin level, and
insulin resistance (HOMA-IR) decreased,
whereas HDL cholesterol and insulin se-
cretion (CIR) increased in both sexes. No
sex difference in any risk factor for diabe-
tes was observed for those who lost3%
body weight (including the placebo
group). Weight loss of 3–7% yielded
greater decreases in 2-h glucose (P 
0.01), insulin concentration (P  0.04),
and insulin resistance (P  0.03) in men
than women. Weight loss of 7% re-
sulted in greater decreases in 2-h glucose
(P  0.01), triglyceride level (P  0.01),
and A1C (P 0.03) in men than women
(Table 3).
Progression to diabetes
Sequential Cox proportional hazards
models revealed no independent effect of
sex on diabetes risk in ILS or placebo
group participants after adjustment for
baseline and time-dependent variables
(data not shown). However, among those
who progressed to diabetes during the
DPP, we observed significant differences
with respect to the manner in which men
and women were diagnosed. Although a
similar proportion of men (15.6%) and
women (14.5%) were diagnosed by fast-
ing glucose criteria alone, women were
more likely than men to convert by 2-h
glucose alone (66.1 vs. 54.4%, respec-
tively) and men were more likely to con-
vert on the basis of fasting and 2-h glucose
together (30.0 vs. 19.4%) (P  0.02 for
all).
CONCLUSIONS— In the DPP life-
style cohort, meeting the 7% weight loss
goal via a hypocaloric low-fat diet and
150 min per week of moderate-intensity
physical activity was strongly correlated
with the prevention of diabetes in both
sexes. Although men in the ILS group lost
significantly more weight and reported
more physical activity than women, their
rate of progression to diabetes (or regres-
sion to normal glucose tolerance) was the
same. The present analyses suggest that
the lack of greater benefit in the men may
have been caused by a greater load of
baseline risk factors. Of the cardiometa-
bolic and diabetes risk factors assessed at
baseline, women had higher risk in two
(higher BMI and less physical activity),
whereas men had higher risk in six (older
age; higher fasting glucose level, waist cir-
cumference, and blood pressure; and
lower HDL and insulin secretion). We ex-
plored the possibility that lack of greater
benefit in the men could be due to a
weaker effect of ILS on risk factors for di-
abetes in men versus women. To control
for sex difference in levels of success with
ILS, groups were stratified by weight loss
as an objective measure of adherence
(since diet and activity information was
Table 1—Baseline characteristics and risk factors for cardiovascular disease and/or diabetes of study participants randomized to ILS or placebo
ILS Placebo
Men Women Men Women
n (%) 345 (32) 734 (68)* 335 (31) 747 (69)*
Age (years) 54.0  17.4 47.8  14.5* 53.1  15.2 48.3  12.9*
Race/ethnic group (n %	)
White 199 (57.7) 381 (51.9) 184 (54.9) 402 (53.8)
African American 50 (14.5) 154 (21.0) 57 (17.0) 163 (21.8)
Hispanic 58 (16.8) 120 (16.3) 57 (17.0) 111 (14.9)
American Indian 31 (9.0) 26 (3.5) 7 (2.1) 52 (7.0)
Asian 7 (2.0) 53 (7.2) 30 (9.0) 19 (2.5)
Cardiometabolic risk factors
Fasting glucose (mmol/l) 5.9  0.7 5.8  0.6* 6.0  0.7 5.8  0.6*
TG (mmol/l) 2.01  1.45 1.76  1.29* 2.01  1.32 1.94  1.36
HDL (mmol/l) 1.01  0.7 1.22  0.41* 1.01  0.26 1.16  0.39*
BP (mmHg) 124/80  18/13 121/78  20/13* 125/80  18/13 121/77  20/13*
Waist circumference (cm) 106.5  17.7 101.8  19.0* 105.9  17.2 103.0  20.4*
BMI (kg/m2) 30.9  6.2 33.6  8.6* 30.9  7.1 34.1  9.6*
Activity
Leisure(MET/h) 13.8  22.4 8.1  12.8* 15.6  24.1 8.1  14.8*
Recreational (MET/h) 70.5  57.0 57.4  52.3* 70.9  53.6 55.5  48.8*
Caloric intake (kcal) 2,065  1,149 1,789  1,041* 1,990  1,178 1,851  1,019*
% on meds for TG or BP 22.0 17.8 21.2 15.7†
% women on HRT – 24.4 – 20.6
Diabetes risk factors
2-h glucose (mmol/l) 9.0  1.6 8.9  1.5 9.0  1.6 9.0  1.6
A1C (%) 5.9  0.6 5.9  0.6 5.9  0.7 5.9  0.6
Insulin (pmol/l) 138  102 144  108 144  90 144  102
Index of insulin secretion
CIR 0.49  0.4 0.56  0.41* 0.52  0.49 0.57  0.44*
Index of insulin action
HOMA-IR 6.0  4.6 6.0  4.9 6.4  4.2 6.2  4.7
Data are medians interquartile range unless otherwise indicated. Twenty Pacific Islanders were included in the “Asian” group. Physical activity data are based on
responses to the Modifiable Activity Questionnaire. MET-hours represent the average amount of time engaged in specified physical activities multiplied by the MET
value of each activity. BP, blood pressure; HRT, hormone replacement therapy; TG, triglyceride. *P  0.01, men vs. women; †P  0.05, men vs. women.
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based on self-report) and also because
weight loss is more closely related to dia-
betes prevention than the manner in
which it occurs (8). When stratified by
weight loss, reduction in cardiometabolic
and diabetes risk factors was actually
greater in men than in women. Neverthe-
less, fasting glucose was only slightly
modified by ILS and appeared to be more
important in the development of diabetes
in men than the development of diabetes
in women. Greater success with ILS did
not translate into reduced incidence of di-
abetes in men versus women, in part be-
cause of the higher baseline risk factors,
especially fasting glucose concentration,
in men in the DPP.
With more numerous risk factors at
baseline, men conceivably had a greater
risk for diabetes than women from the
outset of the DPP. Cox proportional haz-
ards modeling adjusted for age and eth-
nicity demonstrated a nonsignificant
trend toward a 20% higher risk of diabe-
tes in male than in female placebo partic-
ipants in the DPP (P 0.08). Several large
trials, including the Strong Heart Study
(9) and the Women’s Health Study (10),
contend that the type and/or potency of
cardiometabolic and diabetes risk factors
may be different in men and women. In
particular, older age, higher blood pres-
sure, and the presence of metabolic syn-
drome have been shown to convey greater
cardiometabolic and/or diabetes risk in
women (11,12). Certainly, diabetes itself
has long been appreciated as a stronger
relative risk factor for cardiovascular dis-
ease in women (13). Therefore, the fact
that older age, higher plasma fasting glu-
cose, and features of metabolic syndrome
were more common in men than women
at baseline in the DPP makes it worth con-
sidering whether the more numerous
baseline risk factors in men actually con-
ferred greater diabetes risk or simply
equalized the risk between the sexes. A
meta-analysis of 16 trials comparing the
impact of sex with that of risk factors for
cardiovascular disease revealed that car-
diometabolic risk could be predicted by
cardiometabolic risk factors but not by
sex per se (14). In sum, men in the DPP
had more numerous risk factors than
women, presumably making their base-
line risk for diabetes higher. Whether
these risk factors modified disease risk
differently in men versus women in the
DPP remains speculative.
Higher fasting glucose concentration
in men versus women in the DPP is con-
sistent with repeated observations in pop-
ulation studies (15,16). Although both
fasting and 2-h glucose concentrations
are positively associated with diabetes
risk, diabetes incidence rises exponen-
tially as fasting glucose levels increase but
only linearly when 2-h glucose levels in-
crease (17). Therefore, when participants
were enrolled in the DPP (requiring ele-
vation of both fasting and 2-h glucose val-
ues), the men started with higher diabetes
risk due to higher initial fasting glucose
values. Strong evidence exists that those
with high fasting and 2-h glucose values
progress to diabetes more rapidly than
those with only one or the other (18,19).
Although no overall sex difference was
observed in incident diabetes in the DPP,
sex difference in manner of diagnosis was
observed. More women than men pro-
gressed to diabetes based on 2-h glucose
criteria, whereas more men than women
progressed based on the combination of
fasting and 2-h glucose criteria. Together,
these observations highlight the impor-
tance of fasting hyperglycemia as a risk
factor and route of progression to diabetes
in men.
Strengthening its role as a pivotal risk
factor, fasting glucose was only modestly
affected by lifestyle intervention. ILS im-
proved many risk factors for diabetes
among participants of the DPP but ap-
peared to be more robust in lowering 2-h
than fasting glucose levels. In those ran-
domized to ILS, 2-h glucose concentra-
tion during the OGTT fell 5–26%,
whereas fasting glucose concentration fell
only 1–8%. Two-hour glucose concentra-
tion decreased steadily in response to in-
creased success with ILS in both men and
women; however, among those who lost
3% body weight, the decrease was
greater in men. Although no weight
change was noted among placebo partic-
ipants in the DPP, a decrease in 2-h glu-
cose at year 1 was seen in men but not
women. This may relate to the fact that
men were more physically active than
women upon entry and throughout the
DPP. Consistent with the recently pub-
lished AusDiab study (20), 2-h glucose
appears to be more strongly modified by
physical activity than fasting glucose, and
the effect may be independent of weight
loss.
The greater decline in 2-h glucose in
men versus women who lost 3% body
weight in the DPP might be explained by
sex differences in glucose uptake and ox-
idation during physical activity (21).
Clinical studies suggest that men rely pro-
portionately more on carbohydrate and
women proportionately more on lipid
during submaximal physical activity
(21,22). This is evidenced by a higher re-
spiratory exchange ratio in men (21,22)
during exercise at a similar intensity. The
preferential use of carbohydrate as a fuel
Table 2—Percent change in risk factors for cardiovascular disease and diabetes over year 1 in
those randomized to placebo
Men Women
n 335 747
Cardiometabolic risk factors
Fasting glucose 0.0  11.9 0.9  11.9
TG 5.1  46.8 5.1  40.8
HDL 0.0  15.6 0.0  17.6
BP 0.8/1.3  13/14 0.9/1.3  13/16
Waist circumference 0.2  4.8 0.5  6.1
Weight 0.0  3.7 0.1  4.5
BMI 0.0  3.8 0.1  5.2
Physical activity 12.5  125 6.6  162
Caloric intake 8.5  42.7 9.7  36.9
% on meds for TG or BP 0.5 8.3
Diabetes risk factors
2-h glucose 6.9  30.4 4.8  27.5†
A1C 0.02  0.06 0.00  0.06
Insulin 5.0  53.2 0.0  57.1
Index of insulin secretion
CIR 4.1  57.1 2.3  59.4
Index of insulin action
HOMA-IR 5.3  61.0 0.2  64.9
Data are medians  interquartile range. BP, blood pressure; TG, triglyceride. †P  0.05, men vs. women.
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during physical activity in men would
mandate postexercise repletion of glucose
stores and might explain the greater low-
ering of 2-h glucose among men with
3% weight loss in the DPP. In addition
to 2-h glucose concentration, numerous
diabetes and cardiometabolic risk factors
were favorably modified by weight loss
from ILS. Among those who lost 3%
body weight, men appeared to have
greater risk factor reduction with respect
to insulin concentration and insulin resis-
tance (at 3–7% weight loss), as well as
triglyceride concentration and A1C (at
7% weight loss). Although the trends
were not consistent between strata of
weight loss (as with 2-h glucose), they cu-
mulatively represent improved insulin ac-
tion, which also likely relates to greater
active lean mass in men compared with
women.
Several limitations of the current
study are worth noting. First, although
randomized, the study was not balanced
with respect to sex or powered to examine
sex differences a priori. Post hoc analyses
may yield erroneous results, especially
when making multiple comparisons. Sec-
ond, data on physical activity and dietary
intake were self-reported and lack the ro-
bustness of a supervised intervention. Fi-
nally, the physiological or behavioral
basis for the greater success in meeting
ILS goals among men versus women is
unknown.
In summary, meeting the 7% weight
loss goal through ILS strongly correlated
with the prevention of diabetes in the DPP
participants. Surprisingly, in the ILS
group, men lost significantly more weight
and were more active than women and yet
incident diabetes (or return to normal
glucose tolerance) did not differ signifi-
cantly by sex. The present analyses sug-
gest that the lack of greater benefit in the
men may have been obscured by their
more numerous and/or more severe base-
line risk factors, especially fasting glucose
concentration, which was modified only
modestly by ILS. Fasting and 2-h glucose
concentration may impart different risk
for diabetes in men and in women, in that
progression to diabetes appeared more
dependent on fasting glucose in men and
more dependent on 2-h glucose in
women. Prospective studies powered to
examine sex-specific consequences of
different prevention strategies would be
useful.T
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